Clinical trialNCT00830804CompletedPhase 2Interventional

Safety and Effectiveness of Raltegravir Plus Darunavir/Ritonavir in Treatment-Naive HIV-Infected Adults

SponsorAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other InfectionsEnrollment113HIV-1 Infections

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to assess the effectiveness and safety of an antiretroviral therapy (ART) regimen consisting of raltegravir (RAL) and darunavir (DRV)/ritonavir (RTV) as first-line therapy in treatment-naïve participants.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Joseph J. Eron, Jr., MD
University of North Carolina, Chapel Hill
Study ChairKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

22 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Alabamatherapeutics Crs
Birmingham, Alabama, United States
Stanford Crs
Palo Alto, California, United States
Ucsd, Avrc Crs
San Diego, California, United States
Ucsf Aids Crs
San Francisco, California, United States
University of Colorado Hospital Crs
Aurora, Colorado, United States
Georgetown University Crs
Washington D.C., District of Columbia, United States
Northwestern University Crs
Chicago, Illinois, United States
Beth Israel Deaconess Med Center
Boston, Massachusetts, United States
Brigham and Women'S Hosp. Actg Crs
Boston, Massachusetts, United States
Washington U Crs
St Louis, Missouri, United States
Aids Community Health Ctr. Actg Crs
Rochester, New York, United States
Unc Aids Crs
Chapel Hill, North Carolina, United States
Duke Univ. Med. Ctr. Adult Crs
Durham, North Carolina, United States
Univ. of Cincinnati Crs
Cincinnati, Ohio, United States
Case Crs
Cleveland, Ohio, United States
Metrohealth Crs
Cleveland, Ohio, United States
the Ohio State Univ. Aids Crs
Columbus, Ohio, United States
Hosp. of the Univ. of Pennsylvania Crs
Philadelphia, Pennsylvania, United States
University of Pittsburgh Ctu
Pittsburgh, Pennsylvania, United States
the Miriam Hospital
Providence, Rhode Island, United States
Vanderbilt Therapeutics Crs
Nashville, Tennessee, United States
Houston Aids Research Team
Houston, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Darunavir →Raltegravir →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 30 Apr 2009
Primary completion: 28 Feb 2010
Completion: 30 Sept 2010
Last update posted: 8 Nov 2018
Registered enrollment: 113
Registry id: NCT00830804

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.